S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

YMAB Y mAbs Therapeutics Inc

13.19

-1.68 (-11.30%)

After Hours

Last Updated: 15:06:12

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The shares filed today will be sold by Gad Enterprises, LLC, Thomas Gad, Manager

Date of Notice

09/13/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Thomas Gad

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Y mAbs Therapeutics Charts.

Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Y mAbs Therapeutics Charts.

Y mAbs Therapeutics Inc News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 8 November 2024 (4 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 8 November 2024 (4 days ago) • Edgar (US Regulatory)

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
Friday 8 November 2024 (4 days ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 4 November 2024 (1 week ago) • Edgar (US Regulatory)

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
Monday 4 November 2024 (1 week ago) • GlobeNewswire Inc.

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
Friday 25 October 2024 (3 weeks ago) • GlobeNewswire Inc.

Y-mAbs to Participate in Upcoming Investor Conferences in October
Tuesday 1 October 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 20 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 17 September 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 13 September 2024 (2 months ago) • Edgar (US Regulatory)

More Y mAbs Therapeutics Inc News Articles

Moon Equity (PK)

Ronn Motor (PK)

TransCode Therapeutics

Kraig Biocraft Laborator... (QB)

Good Vibrations Shoes (PK)

Code Green Apparel (PK)

Digital Brand Media and ... (PK)

Clean Vision (QB)

Movement Industries (PK)

FuelCell Energy

Fannie Mae (QB)

Valiant Eagle (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions